Experimental Myeloma Agent Shows Promise in Combination with Immunotherapies
Inhibiting a key protein in the tumor microenvironment using…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreInhibiting a key protein in the tumor microenvironment using…
Amgen announced that its RANKL inhibitor, Xgeva (denosumab) met…
A three-drug therapy combination consisting of Darzalex (…
Understanding how multiple myeloma develops and responds to therapies…
High-risk multiple myeloma patients may benefit markedly from galinpepimut-S,…
Robots can do all sorts of tasks to improve…